Merrill, Mwanasha
Mayo Clinic
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Citations 2
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
Merrill, Mwanasha H. , Lambert, Nicholas , Pullarkat, Priyanka, Amoozgar, Behzad , Leslie, Lori A. , Crombie, Jennifer L. , Khurana, Arushi , Nowakowski, Grzegorz S. , Maddocks, Kami J. , Rutherford, Sarah C. , Okwali, Michelle, Batlevi, Connie Lee , Armand, Philippe , Qualls, David , Qualls, David A , Merrill, Mwanasha , Redd, Robert , Caimi, Paolo F. , Godby, Richard , Bond, David A. , Wehmeyer, Graham T. , Romancik, Jason T. , Nastoupil, Loretta J. , Abramson, Jeremy S. , Kahl, Brad S. , Buege, Michael J. , Salles, Gilles
HemaSphere | November 18, 2025 | Volume: 9 | Issue: 11 | Pages: No page available
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
Qualls, David , Lambert, Nicholas , Caimi, Paolo F. , Merrill, Mwanasha H. , Pullarkat, Priyanka, Bond, David A. , Wehmeyer, Graham T. , Romancik, Jason T. , Amoozgar, Behzad , Leslie, Lori A. , Crombie, Jennifer L. , Khurana, Arushi , Nowakowski, Grzegorz S. , Maddocks, Kami J. , Rutherford, Sarah C. , Okwali, Michelle, Seshan, Venkatraman , Batlevi, Connie Lee , Qualls, David A , Merrill, Mwanasha , Bond, David A , Wehmeyer, Graham T , Romancik, Jason T , Nastoupil, Loretta J , Crombie, Jennifer L , Abramson, Jeremy S , Buege, Michael J , Seshan, Venkatraman , Batlevi, Connie L , Salles, Gilles A , Caimi, Paolo F , Godby, Richard , Nastoupil, Loretta J. , Abramson, Jeremy S. , Kahl, Brad S. , Buege, Michael J. , Salles, Gilles
Blood | September 22, 2023 | Volume: 142 | Issue: 26 | Pages: 2327-2331
Abstract In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.